glp-1 therapy kenner Hot take: both sides are oversimplifying GLP-1s. We should be asking harder questions about GLP-1s—research, marketing, long-term outcomes. And yes—some points are valid: • weight loss is variable • regain after stopping There's a new fad in

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor

Even with insurance, there's often a lot of what we step therapy, a lot of hoops or prior medications that you have to attempt first In a recent interview with Pharmaceutical Executive, Doug Long, VP, industry relations, IQVIA, discussed how the increased demand for this drug class is creating reimbursement challenges and altering distribution models

A study using the Control of Eating Questionnaire (CoEQ) has reported that semaglutide treatment reduced hunger, appetite, and interest in high-palatability foods while also diminishing the pleasure of eating [17]

Distinguishing between expected side effects and potentially serious complications is essential for patient safety

Counterintuitively, mice completely defective for the GLP-1 receptor were reported to be protected from high-fat diet-induced peripheral Insulin resistance (177) and, consistently with this, central inhibition of GLP-1R signaling with the antagonist exendin 9-39 improves glucose tolerance and glycaemia (178)